Stoke Therapeutics develops RNA-based medicines, led by zorevunersen, a candidate in clinical testing for Dravet syndrome, a severe genetic epilepsy. It last closed at $26.41 on Nov 17, down 0.83% on the day. In the past 30 days there were 1 dark pool print totaling $5.3M, the largest $5.3M.
Only 1 firm rated STOK in the past 90 days, not enough for a consensus
Average 12-month target
$40.00
▲ 51.5% upside
Based on 1 analyst who set a price target on STOK in the past 90 days. The average target is $40.00, with a high of $40.00 and a low of $40.00, compared with the last close of $26.41.
Low $40.00Avg $40.00High $40.00
Blue marker: last close $26.41
Highest target$40.00
Average target$40.00
Lowest target$40.00
Latest rating changes
JP MorganReinstated
Aug 21Buy$40
GuggenheimReiterated
Aug 4Buy$60
WedbushMaintained
Aug 4Buy$40
Canaccord GenuityMaintained
Aug 4Buy$58
Goldman SachsInitiated
Jul 13Buy$44
Date
Firm
Action
Rating
Price target
Aug 21
JP Morgan
Reinstated
Buy
$40
Aug 4
Guggenheim
Reiterated
Buy
$60
Aug 4
Wedbush
Maintained
Buy
$40
Aug 4
Canaccord Genuity
Maintained
Buy
$58
Jul 13
Goldman Sachs
Initiated
Buy
$44
Loading…
Technical Analysis
STOK · as of the Nov 17 close · updated after every close
Moving sideways
The stock sits between its 20 and 50 day averages. It is 16% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 50). The nearest support is the 50 day average at $26.32, and the nearest resistance the 20 day average at $26.46.
Short trendNeutral
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 4.6%/day
Key levels
$40.2252 week high+52.3%
$30.75200 day average+16.4%
$28.72100 day average+8.7%
$26.98Pivot R1+2.2%
$26.69Swing high (Sep 30)+1.1%
$26.57Pivot+0.6%
$26.4620 day average+0.2%
$26.41Last close
$26.3250 day average−0.3%
$26.01Pivot S1−1.5%
$24.52Swing low (Oct 26)−7.2%
$22.0552 week low−16.5%
Indicators
RSI (14)
49.69
Middle of its range
Neutral
MACD
0.18
Above its signal line
Bullish
Stochastic
35.8
Middle of its range
Neutral
ADX (14)
16.1
No clear trend
Williams %R
-75.7
Oversold below −80, overbought above −20
Neutral
CCI (20)
12.2
Oversold below −100, overbought above 100
Neutral
Rate of change
−2.1%
Change over 10 sessions
Bearish
ATR (14)
$1.21
Typical daily range, 4.6% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNormal
VolatilityNormal, 11.0%/day
Key levels
$40.2252 week high+52.3%
$30.75200 day average+16.4%
$28.72100 day average+8.7%
$26.98Pivot R1+2.2%
$26.69Swing high (Sep 30)+1.1%
$26.57Pivot+0.6%
$26.4620 day average+0.2%
$26.41Last close
$26.3250 day average−0.3%
$26.01Pivot S1−1.5%
$24.52Swing low (Oct 26)−7.2%
$22.0552 week low−16.5%
Indicators
RSI (14)
43.43
Middle of its range
Neutral
MACD
-1.31
Below its signal line
Bearish
Stochastic
37.8
Middle of its range
Neutral
ADX (14)
16.6
No clear trend
Williams %R
-63.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
-47.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−9.0%
Change over 10 sessions
Bearish
ATR (14)
$2.90
Typical daily range, 11.0% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Above
MA 200–
What happened before, for STOK
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how STOK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow STOK usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How STOK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether STOK is in one of them and how their past STOK trades turned out.
Stoke Therapeutics is a biopharmaceutical company based in Bedford, Massachusetts, that develops RNA-based medicines. Its TANGO approach uses antisense oligonucleotides to raise levels of specific proteins in diseases caused by a shortage of one working gene copy. Its lead candidate, zorevunersen, is in late stage clinical testing for Dravet syndrome, a severe genetic epilepsy. The company focuses on diseases of the brain and eye and plans to sell its medicines to patients and healthcare providers in the United States, Canada and Mexico.